8 results about "Endotoxemias" patented technology

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

Probiotic compositions comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici in amounts effective for promoting digestive health, decreasing endotoxemia, decreasing diarrhea, decreasing vomiting and increasing the digestibility of foodstuffs in dogs.

The present application relates to the technical field of animal model construction, and specifically discloses a method for constructing an atherosclerotic plaque thrombosis model. ‑ / ‑ The method comprises the following steps: 1) selecting an ApoE The method provided by the present application is simple in operation, high in repeatability, and can induce atherosclerotic plaque thrombosis under the stimulation of a low-dose LPS, and can obtain a thrombosis rate comparable to that of the prior art, and can be closer to the formation of atherosclerotic thrombosis related to clinical endotoxemia, and better simulate the clinical pathological process.

The invention belongs to the field of treatment of inflammatory diseases, and provides application of an EED inhibitor in preparation of a medicine for preventing and treating blood-brain barrier permeability injury caused by endotoxemia. Experiments show that the EED inhibitor significantly reduces blood brain barrier permeability, inhibits neuroinflammation and improves disease behaviors. The invention provides a new medicine and a new way for treating secondary diseases related to endotoxemia.

There is provided a liposomal suspension comprising transmembrane pH-gradient liposomes in an aqueous solution, the suspension comprising citric acid anhydrous and lipids in a ratio of (3.54 g / L) / (6.49 g / L) along with a kit for preparing the liposomal suspension, uses of the liposomal suspension and kits for treating an ammonia- or ammonia methylated analog-associated disease or disorder, or a symptom thereof; endotoxemia; or endotoxemia-associated disease or disorder or a symptom thereof, in a subject in need thereof. Also provided are a system and method for intraperitoneally administering the liposomal suspension to a subject in need thereof.

The invention relates to application of a curcumin analogue C1 in preparation of a medicine for treating endotoxemia, and relates to the technical field of biological medicines. According to the application, after an endotoxin-induced mouse model is intervened by adopting the curcumin analogue C1, TNF-alpha, IL-6, MCP-1, BUN and BNP in serum are all found to be remarkably reduced, and the pathological injury condition of lung tissues and the survival rate / clinical state of mice are all remarkably improved, the pharmacological value of the curcumin analogue C1 in endotoxemia is disclosed, and the curcumin analogue C1 can be used for treating endotoxemia. And a new thought is provided for treatment of inflammatory diseases.

The present invention relates to the use of an improved curcuminoids composition for reducing LPS levels in blood, reducing endotoxemia, protecting the integrity of the intestinal barrier, treating, decreasing and / or preventing leaky gut syndrome, reducing intestinal lipids absorption, reducing ApoB48 levels in blood and / or for in treating, decreasing and / or preventing dyslipidemia in a subject.